Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rotavirus vaccine-MCM Vaccines B.V.-diphtheria-tetanus-pertussis-hepatitis B-poliomyelitis-Haemophilus influenzae type b infection
- Development stage
- Unknown
- Lead developer
- MCM Vaccine Co
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Oral
01
Overview
This drug entry refers to the concomitant administration of a rotavirus vaccine and the hexavalent combination vaccine Vaxelis (DTaP-HBV-IPV-Hib), developed by MCM Vaccines B.V. (a joint venture between Merck and Sanofi). Vaxelis is indicated for active immunization against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive disease caused by Haemophilus influenzae type b in infants and toddlers. It combines antigens from Sanofi (Diphtheria, Tetanus, Pertussis, and Polio) and Merck (Hib and Hepatitis B). The rotavirus vaccine component (such as RotaTeq or Rotarix) provides protection against rotavirus gastroenteritis through live-attenuated viral strains. This combination is typically administered as part of a routine pediatric vaccination series at 2, 4, and 6 months of age.
- Brand names
- VaxelisRotaTeqRotarix
- Other names
- Vaxelis + rotavirus vaccineDTaP-HBV-IPV-Hib + rotavirus vaccineV419 + rotavirus vaccinePR5I + rotavirus vaccine
02
Targets
MHC II (Major histocompatibility complex class II receptor)BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on rotavirus vaccine-MCM Vaccines B.V.-diphtheria-tetanus-pertussis-hepatitis B-poliomyelitis-Haemophilus influenzae type b infection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rotavirus vaccine-MCM Vaccines B.V.-diphtheria-tetanus-pertussis-hepatitis B-poliomyelitis-Haemophilus influenzae type b infection.